细胞周期调节失控是肿瘤细胞特征之一，然而其分子机制尚不清楚。本课题旨在既往RNA结合蛋白（RNA-binding protein, RBP）调节肿瘤细胞增殖及凋亡的研究基础上，继续研究RNA结合蛋白Roquin在乳腺癌进展中的作用及其机制。本研究前期实验结果已证实 Roquin在几种乳腺癌细胞系和人乳腺癌组织中均呈低表达，且其表达水平与乳腺癌患者存活呈正相关，推测Roquin很可能是一种新型肿瘤抑制基因。因此，本研究拟采用RNA-seq技术、RNA-EMSA、RT-PCR、荧光素酶报告子试验及免疫印迹等体外实验技术；连同NOD-scid IL2rγnull (NSG)小鼠体内成瘤实验；结合临床乳腺癌患者样本数据分析，从而从分子-细胞-动物-临床等水平系统阐明Roquin在乳腺癌进展中的调控作用，为将来基因靶向抗肿瘤寻找新的分子靶标。

Cell cycle dysregulation is one of the hallmarks of tumor cells. However, the underlying molecular mechanisms remain poorly defined. Here, based on our previous study of RNA-binding protein (RBP) on tumor cell proliferation and apoptosis, this project aimed to study the role of Roquin in the progression of breast cancer. The data from the pilot experiments shown that Roquin is lower in several tested breast cancer cell lines and human breast cancer tissues, and its mRNA expression level is positively correlated with the survival of breast cancer patients, which suggesting Roquin is very likely to be a tumor suppressor. Therefore, this study intends to use RNA-seq, RNA-EMSA, RT-PCR, luciferase reporter assay and immunoblotting; combine with NOD-scid IL2rγnull (NSG) mice in vivo tumorigenesis test; together with analysis of breast cancer patient data to systematically elucidate the role of Roquin in the progression of breast cancer. Together, this study is expected to find new molecular targets for future tumor gene-targeted therapy.